56% of Americans Call GLP-1 Drug Costs a Barrier While Medicare's $50 Program Reaches Only Some Patients
An Ipsos survey for the American Diabetes Association found that 56% of Americans view GLP-1 costs as a barrier, amid high prices, coverage gaps and limited Medicare assistance.
Medical Daily ·